Rise Advisors’s Sutro Biopharma STRO Stock Holding History

Rise Advisors’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-77	Closed	-$668	–	1258
2025 Q3	$668	Hold	77	–	–	﹤0.01%	1340
2025 Q2	$549	Buy	+77	New	+$630	﹤0.01%	1392

Other funds holding STRO

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Rise Advisors's STRO Position: Q4 2025 in Review

Rise Advisors sold out of Sutro Biopharma (STRO) in Q4 2025, closing a stake of 77 shares — an estimated $668 sold.

Rise Advisors first reported a position in STRO in Q2 2025 and held it in 2 quarters. The position peaked at $668 in Q3 2025. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

Rise Advisors reported no remaining Sutro Biopharma position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 77 Sutro Biopharma shares in Q4 2025, an estimated $668.
Rise Advisors first reported a position in Sutro Biopharma in Q2 2025 and held it in 2 quarters.
Rise Advisors's Sutro Biopharma position peaked at $668 in Q3 2025.
63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.